CRISPR/Cas9 novel therapeutic road for the treatment of neurodegenerative diseases
release_ish7dxnw6bcrnockcfrgbfbzta
[as of editgroup_5fxc56whcjcw5f5rmlfw6jqktu]
by
Ansar Karimian, Negar Gorjizadeh, Forough Alemi, Zatollah Asemi, Khalil Azizian, Jafar Soleimanpour, Faezeh Malakouti, Niloufar Targhazeh, Maryam Majidinia, Bahman Yousefi
Abstract
CRISPR (clustered regularly interspaced short palindromic Repeats)/Cas9 is a new genetic editing technology that can be a beneficial method to advance gene therapy. CRISPR technology is a defense system of some bacteria against invading viruses. Genome editing based on the CRISPR/Cas9 system is an efficient and potential technology that can be a viable alternative to traditional methods. This system is a compound of a short guide RNAs (gRNAs) for identifying the target DNA sequence and Cas9 protein as nuclease for breaking and cutting of DNA. In this review, recent advances in the CRISPR/Cas9-mediated genome editing tools are presented as well as their use in gene therapy strategies for the treatment of neurological disorders including Parkinson's disease, Alzheimer's disease, and Huntington's disease.
In text/plain
format
Archived Content
There are no accessible files associated with this release. You could check other releases for this work for an accessible version.
access all versions, variants, and formats of this works (eg, pre-prints)
Crossref Metadata (via API)
Worldcat
SHERPA/RoMEO (journal policies)
wikidata.org
CORE.ac.uk
Semantic Scholar
Google Scholar